Adicet Bio, Inc. Common Stock CG 46th Annual Growth Conference

Thanks. Absolutely. First of all, John, thank you very much for inviting us.

Very timely. We expect to have very significant disclosures in the very near future. So excited to be here and talk about the data we expect to share. Adicet is a leading cell therapy focused on off-the-shelf cell therapies for autoimmune diseases and for oncology indications. We also have an in vivo CAR T pipeline that we expect to disclose in the very near future. Our lead asset, ADI-001, is an off-the-shelf gamma delta one cell therapy targeting CD20 for autoimmune diseases. Our next disclosure this quarter is expected to be in LN and SLE. This will be, I believe, the largest data set ever reported by an allogeneic off-the-shelf cell therapy in the field of LN and SLE, which probably shows the excitement that physicians and patients have in our study.

The only other companies that have comparable number of patients reported in LN and SLE that are cell therapies are small companies like Novartis and Bristol Myers Squibb. We're glad to be in that company. No other company, as far as we know, also either allogeneic or actually autologous, has reported this type of data set, and certainly not bispecifics. We have another asset going into clinical studies, and that is for prostate cancer. It's an off-the-shelf gamma delta one cell therapy that targets a validated binding modality on the PSMA consistent with PLUVICTO, with two very important bolt-on technologies that are a result of about four years of research that makes the cell very potent and address some of the key challenges that we have seen with cell therapies in solid tumors. Happy to elaborate about that.

We also expect a disclosure about our in vivo pipeline, which also has been in the work for a long time, in the very near future. There's going to be a lot coming from us in the next few months.

Thanks. Yeah, absolutely. Maybe I'll start by focusing on the targets, then I'll kind of step back and focus on our therapy versus autologous.

Regarding the targets, actually, most of the validation in this field has been primarily on CD19. When we look at our data with CD20, you couldn't actually tell the difference. What you want to see is complete depletion of B cells in the blood, and we actually look also at the CD19 B cell depletion in the blood, and we see absolute complete depletion of CD19 in the blood. That's number one. Actually, more important is complete depletion of CD19 B cells in the lymph nodes. It's the tissue penetration that matters. When we look at our biopsies from lymph nodes, we consistently see complete depletion of CD19 B cells in the lymph nodes.

I don't think we've identified one CD19 positive B cell when we look at the lymph nodes that we have obtained so far. Then you want to see that once the immune system recovers, it recovers as a naive immune system, and that has been consistent with all of the patients that we have tested that at least announced so far. We see complete immune reset, whether it's CD19 or CD20. Happy to focus about the differentiation of our program versus others if you want, or we can discuss it later. Whatever you prefer. Sure. That's okay.

Sure. Absolutely. We have enrolled in 5 countries. One of the key advantages that we have, we can actually enroll in centers that do not necessarily do cell therapy studies because this is such a well-tolerated and off-the-shelf therapy that doesn't require leukapheresis. Physicians can make this available to their patients. We actually had much more interest in the product. At some point, we said, "Hey, we have enough patients. Wait, because we want to start a pivotal study. We don't need more patients now." We were in that position. We could've enrolled many more patients. I want to be very clear. We stopped at some point. We expect to share data from 22 patients that have been enrolled. We really wanted to see at least 12 months data. Out of the 22 patients, 13 will have at least 12 months follow-up.

These will be primarily LN patients because we started enrolling LN, but we will have some SLE patients, and all the 22 patients will have at least 6 months follow-up.

Yes. Yeah, absolutely. That's really why we focused on the 12 months, because if patients can get a single therapy and then they essentially have a drug-free remission or drug-free complete renal response in at least a year, that's a big step for these patients.